

Stephen P Hunger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5025319/publications.pdf>

Version: 2024-02-01

260
papers

29,110
citations

5896

81
h-index

5539

163
g-index

299
all docs

299
docs citations

299
times ranked

21581
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. <i>Haematologica</i> , 2023, 108, 717-731.	3.5	6
2	The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. <i>Seminars in Cancer Biology</i> , 2022, 84, 144-152.	9.6	47
3	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	1.4	28
4	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALLO232. <i>Leukemia</i> , 2022, 36, 648-655.	7.2	14
5	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR-T-cell therapy. <i>Blood</i> , 2022, 139, 2173-2185.	1.4	39
6	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2022, 8, 354.	7.1	35
7	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. <i>Nature Genetics</i> , 2022, 54, 170-179.	21.4	29
8	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	4.1	12
9	Outstanding outcomes in infants with <i>KMT2A</i> -germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. <i>Haematologica</i> , 2022, 107, 1205-1208.	3.5	11
10	SIOP Strategy 2021-2025: Cure for more, care for all. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29577.	1.5	2
11	Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. <i>Blood</i> , 2022, 139, 3519-3531.	1.4	20
12	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45
13	Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in <i>KMT2A</i> -rearranged leukemia. <i>Blood</i> , 2022, 139, 2198-2211.	1.4	37
14	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	7.2	6
15	Molecular Mechanisms of <i>ARID5B</i> -Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1287-1295.	6.3	10
16	Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1167-1175.	6.3	6
17	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 10023-10023.	1.6	1
18	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 7000-7000.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Genome-Wide Association Study of Susceptibility Loci for <i>TCF3-PBX1</i> Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2021, 113, 933-937.	6.3	9
20	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021, 137, 1550-1552.	1.4	3
21	Molecular basis of <i>ETV6</i> -mediated predisposition to childhood acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 364-373.	1.4	37
22	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28787.	1.5	17
23	Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 168-177.	1.4	35
24	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
25	NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. <i>JCO Precision Oncology</i> , 2021, 1, 204-214.	3.0	36
26	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , the, 2021, 8, e55-e66.	4.6	32
27	Reply to A. K. Agrawal et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 695-696.	1.6	0
28	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. <i>Leukemia</i> , 2021, 35, 1279-1290.	7.2	46
29	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
30	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-cell lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	1.5	9
31	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
32	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	4.7	7
33	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children's Oncology Group AALL1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 10004-10004.	1.6	3
34	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	1.6	56
35	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021, 39, 1540-1552.	1.6	19
36	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity. <i>Journal of Clinical Oncology</i> , 2021, 39, 10002-10002.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 10003-10003.	1.6	0
38	Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	9.4	83
39	Abstract 3028: Integrative genomics reveals lncRNAs associated with pediatric cancer. , 2021, , .		1
40	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Advances, 2021, 5, 2890-2900.	5.2	3
41	Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia. Haematologica, 2021, 106, 2990-2994.	3.5	6
42	Late isolated central nervous system relapse in childhood acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. Pediatric Blood and Cancer, 2021, 68, e29256.	1.5	10
43	Understanding Adolescent and Young Adult 6-Mercaptopurine Adherence and mHealth Engagement During Cancer Treatment: Protocol for Ecological Momentary Assessment. JMIR Research Protocols, 2021, 10, e32789.	1.0	5
44	Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy. Nature Reviews Clinical Oncology, 2021, 18, 677-678.	27.6	9
45	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	20
46	Impact of risk-stratified therapy on health status in survivors of childhood Acute Lymphoblastic Leukemia: a report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0667.2021.	2.5	4
47	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-L) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3487-3487.	1.4	1
48	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. Blood, 2021, 138, 363-363.	1.4	8
49	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. Blood, 2021, 138, 211-211.	1.4	3
50	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. Leukemia, 2020, 34, 1006-1016.	7.2	8
51	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2020, 38, 602-612.	1.6	107
52	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. Cancer Research, 2020, 80, 5189-5202.	0.9	9
53	Recent trends in the results of studies conducted by the Children's Oncology Group acute lymphoblastic leukemia committee and implications for emerging cooperative trial groups in low- and middle-income countries. Pediatric Hematology Oncology Journal, 2020, 5, 151-155.	0.1	5
54	Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. Science Advances, 2020, 6, eaba3064.	10.3	14

#	ARTICLE	IF	CITATIONS
55	Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3418-3429.	1.6	60
56	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	1.6	136
57	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020, 38, 2628-2638.	1.6	41
58	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	1.6	42
59	Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28427.	1.5	61
60	How I treat relapsed acute lymphoblastic leukemia in the pediatric population. <i>Blood</i> , 2020, 136, 1803-1812.	1.4	90
61	ABL-class fusion positive acute lymphoblastic leukemia: can targeting ABL cure ALL?. <i>Haematologica</i> , 2020, 105, 1754-1757.	3.5	1
62	The ASPHO 2020 distinguished career award goes to Dr Garrett M. Brodeur. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28191.	1.5	0
63	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. <i>Haematologica</i> , 2020, 106, 46-55.	3.5	29
64	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 1897-1905.	1.6	117
65	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10510-10510.	1.6	7
66	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13666-e13666.	1.6	1
67	Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10520-10520.	1.6	0
68	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10509-10509.	1.6	3
69	Assessment of the impact of inpatient infectious events in pediatric patients with newly diagnosed acute leukemia at Dr. Robert Reid Cabral Children's Hospital, Dominican Republic. <i>PLoS ONE</i> , 2020, 15, e0243795.	2.5	1
70	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.4	32
71	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. <i>Blood</i> , 2019, 134, 1227-1237.	1.4	37
72	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 873-883.	2.8	41

#	ARTICLE	IF	CITATIONS
73	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2019, 14, e0221288.	2.5	16
74	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. <i>Leukemia and Lymphoma</i> , 2019, 60, 1740-1748.	1.3	25
75	Clinical utility of custom-designed NGS panel testing in pediatric tumors. <i>Genome Medicine</i> , 2019, 11, 32.	8.2	79
76	More Is Not Always Better: The Perils of Treatment Intensification in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1601-1603.	1.6	7
77	Epigenetic silencing of <i>SOCS5</i> potentiates <i>JAK</i> - <i>STAT</i> signaling and progression of T-cell acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 1931-1946.	3.9	24
78	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	1.5	8
79	Bortezomib reinduction chemotherapy in high-risk <i>ALL</i> in first relapse: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 186, 274-285.	2.5	65
80	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 780-789.	1.6	48
81	1681. Assessment of the Impact of Infectious Events in a Cohort of Pediatric Leukemia Patients in the Dominican Republic. <i>Open Forum Infectious Diseases</i> , 2019, 6, S615-S616.	0.9	0
82	Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. <i>JCO Precision Oncology</i> , 2019, 3, 1-26.	3.0	6
83	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	3.5	25
84	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. <i>Oncogene</i> , 2019, 38, 2241-2262.	5.9	29
85	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	21.4	384
86	Novel susceptibility variants at the <i>ERC</i> locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019, 133, 724-729.	1.4	44
87	Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. <i>Blood</i> , 2019, 134, 824-824.	1.4	6
88	Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 10005-10005.	1.6	4
89	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10008-10008.	1.6	31
90	Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10016-10016.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2019, 37, 10033-10033.	1.6	0
92	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature, 2018, 555, 371-376.	27.8	649
93	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. Cancer Medicine, 2018, 7, 3-12.	2.8	13
94	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 2126-2137.	7.2	48
95	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
96	The ASPHO 2018 Distinguished Career Award goes to Dr. Michael P. Link. Pediatric Blood and Cancer, 2018, 65, e26987.	1.5	0
97	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer, 2018, 124, 1150-1159.	4.1	46
98	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e26928.	1.5	28
99	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood, 2018, 131, 1350-1359.	1.4	158
100	Immunotherapy for ALL takes the world by storm. Nature Reviews Clinical Oncology, 2018, 15, 69-70.	27.6	25
101	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 995-999.	1.4	170
102	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer, 2018, 124, 571-579.	4.1	31
103	Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leukemia and Lymphoma, 2018, 59, 1624-1633.	1.3	37
104	Integrated Risk Stratification Using Minimal Residual Disease and Sentinel Genetic Alterations in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 4-6.	1.6	2
105	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. Journal of Clinical Oncology, 2018, 36, 2306-2314.	1.6	185
106	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
107	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. JNCI Cancer Spectrum, 2018, 2, pky069.	2.9	10
108	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 3094-3114.	8.5	37

#	ARTICLE	IF	CITATIONS
109	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	1.6	164
110	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	27.8	236
111	Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL. <i>Biomarker Research</i> , 2018, 6, 27.	6.8	9
112	Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with <i>GOLGA5-JAK2</i> fusion and induction failure. <i>Haematologica</i> , 2018, 103, e427-e431.	3.5	56
113	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018, 132, 815-824.	1.4	97
114	Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331. <i>Blood</i> , 2018, 132, 1382-1382.	1.4	8
115	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018, 132, 35-35.	1.4	7
116	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018, 132, 261-261.	1.4	3
117	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10500-10500.	1.6	54
118	Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10518-10518.	1.6	1
119	Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4026-4026.	1.4	1
120	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 177-187.	1.4	138
121	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017, 129, 3352-3361.	1.4	236
122	CML in blast crisis: more common than we think?. <i>Blood</i> , 2017, 129, 2713-2714.	1.4	5
123	Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. <i>British Journal of Haematology</i> , 2017, 176, 867-882.	2.5	62
124	Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 2064-2072.	1.4	198
125	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1211-1218.	21.4	693
126	A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26879.	1.5	48

#	ARTICLE	IF	CITATIONS
127	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2700-2707.	1.6	38
128	Reply to I.J. Cohen. <i>Journal of Clinical Oncology</i> , 2017, 35, 3989-3991.	1.6	2
129	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	1.6	64
130	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0 0.1rgBT /Overlock 10		
131	Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. <i>Blood Advances</i> , 2017, 1, 1657-1671.	5.2	76
132	The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) â€“ Mechanisms and Opportunities. <i>Frontiers in Pediatrics</i> , 2016, 4, 49.	1.9	11
133	Outcome of Children with Standardâ€Risk Tâ€Lineage Acute Lymphoblastic Leukemiaâ€”Comparison among Different Treatment Strategies. <i>Pediatric Blood and Cancer</i> , 2016, 63, 255-261.	1.5	17
134	Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. <i>Cancer</i> , 2016, 122, 1017-1028.	4.1	106
135	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016, 34, 2380-2388.	1.6	301
136	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2133-2140.	1.6	88
137	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016, 127, 558-564.	1.4	56
138	Characterization of leukemias with ETV6-ABL1 fusion. <i>Haematologica</i> , 2016, 101, 1082-1093.	3.5	66
139	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	12.8	218
140	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.	21.4	231
141	Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. <i>Cancer</i> , 2016, 122, 1608-1617.	4.1	69
142	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study <scp>AALL0331</scp>. <i>International Journal of Cancer</i> , 2016, 138, 332-339.	5.1	66
143	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	1.6	141
144	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2016, 29, 186-200.	16.8	118

#	ARTICLE	IF	CITATIONS
145	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 919-926.	1.6	111
146	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016, 128, 1086-1086.	1.4	2
147	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. <i>Blood</i> , 2016, 128, 454-454.	1.4	4
148	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 604-604.	1.4	1
149	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 758-758.	1.4	1
150	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, LBA-2-LBA-2.	1.4	3
151	Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG <i>E. coli</i> L-asparaginase): Results from Children's Oncology Group (COG) study AALL07P4.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10508-10508.	1.6	3
152	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2906-2906.	1.4	0
153	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 414-418.	1.5	31
154	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015, 125, 680-686.	1.4	110
155	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015, 126, 964-971.	1.4	287
156	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. <i>Blood</i> , 2015, 126, 2202-2212.	1.4	88
157	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1770-1776.	1.4	102
158	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. <i>Cancer</i> , 2015, 121, 3577-3590.	4.1	59
159	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1171-1175.	1.5	89
160	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	1.5	76
161	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015, 126, 69-75.	1.4	64
162	Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. <i>Blood</i> , 2015, 125, 3977-3987.	1.4	232

#	ARTICLE	IF	CITATIONS
163	Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 364-374.	4.1	49
164	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	16.8	109
165	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015, 6, 7553.	12.8	72
166	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 114-128.	16.8	107
167	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 1759-1767.	1.4	189
168	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 815.	7.4	234
169	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015, 521, 357-361.	27.8	127
170	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. <i>Nature Genetics</i> , 2015, 47, 535-538.	21.4	274
171	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015, 6, 6604.	12.8	281
172	Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3). <i>Pediatric Blood and Cancer</i> , 2015, 62, 419-426.	1.5	61
173	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncology</i> , The, 2015, 16, 1659-1666.	10.7	161
174	Acute Lymphoblastic Leukemia in Children. <i>New England Journal of Medicine</i> , 2015, 373, 1541-1552.	27.0	1,484
175	Reply to: Obesity is an important health problem in survivors of pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2057-2057.	1.5	2
176	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 2938-2948.	1.6	747
177	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015, 126, 807-807.	1.4	5
178	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10006-10006.	1.6	9
179	Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Children's Oncology Group AALL1131.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10007-10007.	1.6	6
180	Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Children's Oncology Group (COG) trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10035-10035.	1.6	4

#	ARTICLE	IF	CITATIONS
181	Neurocognitive function of children treated for high-risk B-acute lymphoblastic leukemia (HR-ALL) randomized to Capizzi (CMTX) versus high-dose methotrexate (HDMTX): A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10002-10002.	1.6	0
182	Association of higher lung dose received during total body irradiation for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia with inferior progression-free and overall survival: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10030-10030.	1.6	3
183	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3716-3716.	1.4	0
184	Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2014, 4, 54.	2.8	117
185	Introduction and overview to issue on new developments in pediatric hematology/oncology. <i>Current Opinion in Pediatrics</i> , 2014, 26, 1-2.	2.0	0
186	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	1.6	91
187	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014, 346, 1373-1377.	12.6	665
188	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	9.4	201
189	Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 87-99.	2.5	61
190	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	27.0	1,161
191	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014, 124, 1266-1276.	1.4	84
192	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology Group (COG) Study AALL0331. <i>Blood</i> , 2014, 124, 793-793.	1.4	15
193	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 612-612.	1.4	0
194	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	1.4	6
195	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Blood</i> , 2014, 124, 132-132.	1.4	1
196	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 128-128.	1.4	0
197	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 284-284.	1.4	0
198	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. <i>Blood</i> , 2013, 121, 485-488.	1.4	156

#	ARTICLE	IF	CITATIONS
199	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 957-963.	1.5	149
200	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 290-294.	21.4	264
201	Predicting relapse risk in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 606-620.	2.5	89
202	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013, 45, 1494-1498.	21.4	264
203	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Journal of the National Cancer Institute</i> , 2013, 105, 733-742.	6.3	208
204	Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 3397-3402.	1.6	125
205	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 242-252.	21.4	588
206	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 60-60.	1.4	1
207	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (Ph-like) or BCR-ABL1-Like Signature For Therapeutic Targeting and Clinical Intervention. <i>Blood</i> , 2013, 122, 826-826.	1.4	65
208	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children's Oncology Group (COG) AALL0331. <i>Blood</i> , 2013, 122, 837-837.	1.4	13
209	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 3868-3868.	1.4	0
210	Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1371-1381.	27.0	252
211	Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2753-2759.	1.6	82
212	Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2012, 119, 1872-1881.	1.4	110
213	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. <i>Blood</i> , 2012, 119, 3512-3522.	1.4	210
214	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 833-842.	1.4	201
215	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 3510-3518.	1.4	263
216	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. <i>Blood</i> , 2012, 120, 3764-3773.	1.4	132

#	ARTICLE	IF	CITATIONS
217	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 153-166.	16.8	621
218	Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1663-1669.	1.6	944
219	Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. <i>Lancet Oncology</i> , The, 2012, 13, 906-915.	10.7	143
220	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012, 481, 157-163.	27.8	1,430
221	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012, 120, 2466-2466.	1.4	5
222	In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 9506-9506.	1.6	0
223	Development and Refinement of Augmented Treatment Regimens for Pediatric High-Risk Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 611-615.	3.8	1
224	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 289-289.	1.4	4
225	Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. <i>Blood</i> , 2011, 117, 3010-3015.	1.4	67
226	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 4169-4173.	1.4	162
227	Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2011, 118, 243-251.	1.4	126
228	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2011, 118, 3080-3087.	1.4	255
229	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. <i>Blood</i> , 2011, 118, 5218-5226.	1.4	180
230	Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906. <i>Pediatric Blood and Cancer</i> , 2011, 57, 569-577.	1.5	55
231	Improving outcomes for high-risk ALL: Translating new discoveries into clinical care. <i>Pediatric Blood and Cancer</i> , 2011, 56, 984-993.	1.5	60
232	Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Anemia. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 361-365.	2.5	37
233	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. <i>Blood</i> , 2011, 118, 1440-1440.	1.4	3
234	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. <i>Blood</i> , 2011, 118, 1510-1510.	1.4	12

#	ARTICLE	IF	CITATIONS
235	Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclox in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience. <i>Blood</i> , 2011, 118, 2580-2580.	1.4	2
236	Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,. <i>Blood</i> , 2011, 118, 3579-3579.	1.4	8
237	MLL Rearrangement and Age At Diagnosis Are Strongly Associated with High Level Surface FLT3 Expression and Ex Vivo Sensitivity to FLT3 Inhibition: A Prospective Analysis of 54 Consecutive Infants with ALL Enrolled in Children's Oncology Group (COG) Trial AALL0631. <i>Blood</i> , 2011, 118, 568-568.	1.4	0
238	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. <i>Blood</i> , 2011, 118, 739-739.	1.4	2
239	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 68-68.	1.4	0
240	Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. <i>Blood</i> , 2010, 116, 4874-4884.	1.4	370
241	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. <i>Pediatric Blood and Cancer</i> , 2010, 54, 872-878.	1.5	22
242	Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. <i>Journal of Clinical Oncology</i> , 2010, 28, 4755-4761.	1.6	203
243	Absence of Biallelic γ TCR Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3816-3823.	1.6	93
244	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 5312-5321.	1.4	503
245	Targeted Microarray Analyses Augment the Clinical Cytogenetic Diagnosis of Acute Lymphoblastic Leukemia (ALL): Submicroscopic Genetic Events Improve Diagnosis, Contribute to Risk Stratification, and Provide Genetic Markers for Minimal Residual Disease (MRD) Testing. <i>Blood</i> , 2010, 116, 2690-2690.	1.4	0
246	Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 5189-5194.	1.6	128
247	JAK mutations in high-risk childhood acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9414-9418.	7.1	516
248	Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5175-5181.	1.6	643
249	Germline genomic variants associated with childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2009, 41, 1001-1005.	21.4	459
250	Rearrangement of CRLF2 in B-progenitorâ€“ and Down syndromeâ€“associated acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2009, 41, 1243-1246.	21.4	559
251	Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2009, 360, 470-480.	27.0	1,260
252	Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3971-3978.	1.6	210

#	ARTICLE	IF	CITATIONS
253	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. <i>Blood</i> , 2008, 111, 5477-5485.	1.4	751
254	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	1.4	413
255	Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?. <i>Pediatric Blood and Cancer</i> , 2005, 45, 876-880.	1.5	24
256	Cytogenetic abnormalities in a case of botryoid rhabdomyosarcoma. , 2000, 34, 293-295.		9
257	Acquisition of p16INK4Aandp15INK4B Gene Abnormalities Between Initial Diagnosis and Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1999, 93, 2380-2385.	1.4	82
258	Acquisition of p16INK4Aandp15INK4B Gene Abnormalities Between Initial Diagnosis and Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1999, 93, 2380-2385.	1.4	4
259	What Significance Should We Attribute to the Detection of MLL Fusion Transcripts?. <i>Blood</i> , 1998, 92, 709-711.	1.4	26
260	Hyperdiploidy and E2A-PBX1 fusion in an adult with t(1;19)+ acute lymphoblastic leukemia: Case report and review of the literature. , 1997, 20, 392-398.		20